A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD)
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs CPI 444 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Vernalis
- 24 Apr 2014 Initial results announced in a Vernalis media release.
- 29 Jul 2013 Planned End Date changed to 1 Jun 2014.
- 29 Jul 2013 Completion is expected in the first half of 2014, according to a Vernalis media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History